Physician
Synergy Healthcare Associates, PLLC
Synergy Healthcare Associates, PLLC was paid $5.92M by Medicaid between Oct 2018 and Dec 2024, across 88 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 29% of everything it billed.
33Billing provider infoSYNERGY HEALTHCARE ASSOCIATES, PLLC
SAN ANTONIO, TX 78232
SAN ANTONIO, TX 78232
33aNPI1356584544assigned 04/17/2009
33bProvider typeObstetrics & Gynecology Physician
28Total paid$5.92M
24GClaims257,442
24DCodes billed88
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in Texas
Rank by total paid#15 of 432
Median peer was paid$103K
This provider vs. median57×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32 | $250.88 | |
| 2019 | 114 | $765.91 | |
| 2020 | 9,949 | $186K | |
| 2021 | 61,909 | $1.38M | |
| 2022 | 69,317 | $1.60M | |
| 2023 | 71,311 | $1.65M | |
| 2024incomplete | 44,810 | $1.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 29% | 37,706 | 31,571 | $1.70M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 32,139 | 27,255 | $1.07M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 12% | 9,693 | 9,392 | $733K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 11% | 8,995 | 8,384 | $645K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 8.5% | 49,517 | 19,282 | $503K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 3,458 | 3,343 | $163K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 1,779 | 1,713 | $133K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.2% | 1,634 | 1,587 | $130K |
| 76830 | Ultrasound, transvaginal | 1.9% | 1,283 | 1,232 | $112K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.7% | 12,638 | 9,220 | $98K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.4% | 1,054 | 990 | $81K |
| 81002 | 1.3% | 28,422 | 20,974 | $77K |
76 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 810 | $51K |
| 90461 | <1% | 12,482 | $47K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 474 | $46K |
| S8301 | Infection control supplies, not otherwise specified | <1% | 3,117 | $41K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,334 | $37K |
| 87634 | <1% | 605 | $34K | |
| 99429 | <1% | 889 | $28K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 331 | $22K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 38 | $21K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 252 | $21K |
| 83655 | <1% | 1,892 | $18K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 284 | $17K |
| 81025 | <1% | 2,044 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 194 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 677 | $7K |
| 0071A | <1% | 136 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 99 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 306 | $4K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 78 | $4K |
| 99381 | <1% | 74 | $4K | |
| CP002 | <1% | 434 | $4K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 480 | $4K |
| 90756 | <1% | 164 | $4K | |
| 99235 | <1% | 25 | $3K | |
| 90715 | <1% | 118 | $3K | |
| 99385 | <1% | 39 | $3K | |
| 92551 | <1% | 1,707 | $2K | |
| 59430 | <1% | 27 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 31 | $2K |
| 0072A | <1% | 28 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $745.02 |
| 88720 | <1% | 291 | $743.26 | |
| 96160 | <1% | 3,016 | $669.76 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 57 | $574.50 |
| 90658 | <1% | 39 | $548.08 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 54 | $545.73 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $501.16 |
| 87807 | <1% | 36 | $374.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 29 | $351.74 |
| 96380 | <1% | 12 | $229.08 | |
| 85014 | <1% | 111 | $182.09 | |
| 80061 | Lipid panel | <1% | 13 | $146.25 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $106.12 |
| 99173 | <1% | 3,381 | $89.66 | |
| 99000 | <1% | 13 | $65.00 | |
| 92552 | <1% | 14 | $55.00 | |
| 85018 | <1% | 103 | $42.45 | |
| 82947 | <1% | 13 | $39.60 | |
| 90686 | <1% | 5,825 | $18.88 | |
| 96161 | <1% | 172 | $18.00 | |
| 36416 | <1% | 3,284 | $6.05 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $1.23 |
| 90680 | <1% | 1,983 | $0.13 | |
| 90670 | <1% | 4,828 | $0.10 | |
| 90671 | <1% | 1,973 | $0.08 | |
| 90656 | <1% | 582 | $0.06 | |
| 90648 | <1% | 4,501 | $0.06 | |
| 90723 | <1% | 3,115 | $0.03 | |
| 90697 | <1% | 1,153 | $0.02 | |
| 90633 | <1% | 1,429 | $0.02 | |
| 90716 | <1% | 620 | $0.01 | |
| 90707 | <1% | 753 | $0.01 | |
| 96127 | 0% | 88 | $0.00 | |
| 90647 | 0% | 98 | $0.00 | |
| 90696 | 0% | 30 | $0.00 | |
| 99459 | 0% | 196 | $0.00 | |
| 90651 | 0% | 29 | $0.00 | |
| 90619 | 0% | 12 | $0.00 | |
| 90681 | 0% | 692 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 1,067 | $0.00 |
| 99188 | 0% | 43 | $0.00 | |
| G9920 | Screening performed and negative | 0% | 95 | $0.00 |
| 0502F | 0% | 14 | $0.00 | |
| 90700 | 0% | 86 | $0.00 | |
| 99177 | 0% | 29 | $0.00 | |
| 90672 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOELFEL, NATHAN (COO)